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UDP-Glucuronosyltransferase (UGT) Genetic Variants and their Potential Role in
Carcinogenesis
Jean Bendaly
ABSTRACT
Exposure to polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene
are important risk factors for cancer. Three UDP-glucuronosyltransferases, UGT1A9,
UGT1A10, and UGT2B7, have been shown to play an important role in the phase II
metabolism of carcinogenic metabolites of BaP. Because UGT1A9 and UGT2B7 are
well-expressed in digestive tract tissues including liver and colon, it is possible that
genetic variations in either enzyme may play an important role in colon cancer risk.
However, UGT1A10 is extrahepatic and is expressed in the oral cavity and the larynx;
therefore, genetic variations in this enzyme may play an important role in risk for
orolaryngeal cancer. This study examined UGT1A9-, UGT1A10-, and UGT2B7-specific
sequences for polymorphisms that play a role in cancer susceptibility. For the UGT1A9
gene, two missense polymorphisms at codons 167 (Val>Ala) and 183 (Cys>Gly) were
identified. A previously-reported missense polymorphism was identified for the
UGT2B7 gene. To assess the potential role of UGT1A10 variants as a risk factor for
orolaryngeal cancer, PCR-RFLP was used to identify UGT1A10 genotypes in DNA
specimens isolated from 115 African American newly-diagnosed orolaryngeal cancer
cases and 115 non-cancer controls individually matched by age and race. A significantly
decreased risk for orolaryngeal cancer was observed for subjects possessing one or more
UGT1A10139Lys alleles as determined by crude analysis or after logistic regression
analysis adjusting for age, sex, smoking and alcohol consumption. These results strongly
vii

suggest that the UGT1A10139Lys polymorphism may play an important protective role in
risk for orolaryngeal cancer. To determine whether the change in amino acid sequence
at codon 183 results in aberrant UGT1A9 enzyme activity, functional characterization of
the wild-type- and variant-encoded UGT1A9 isoforms was performed in vitro. Cell
homogenates were prepared from UGT1A9-transfected HK293 cells and glucuronidation
assays were performed against various carcinogens/carcinogen metabolites. A significant
(p<0.001) 3- to 4-fold decrease in enzyme activity, determined by HPLC analysis, was
observed for the UGT1A9183Gly variant as compared to its wild-type counterpart for all
substrates analyzed. These results demonstrate that the UGT1A9 (Cys183Gly)
polymorphism significantly alters UGT1A9 function and could potentially play an
important role as risk modifier for digestive tract cancers.

viii

LITERATURE REVIEW
From Genes to Proteins
Genes, the basic unit of inheritance, are contained in chromosomes and consist of
deoxyribonucleic acid (DNA) which provides the genetic “blue-print” for all proteins
in the body (Lebowitz et al., 1990). Thus, genes ultimately influence all aspects of body
structure and function. The human is estimated to have 50,000 to 100,000 structural
genes (genes that code for proteins). An error or mutation in one of these genes often
leads to a recognizable genetic disease (Jackson et al., 1991).
The DNA molecule has three basic components: the pentose sugar, deoxyribose; a
phosphate group; and four types of nitrogenous bases. Two of these bases, cytosine
and thymine, are single carbon-nitrogen rings called pyrimidines. The other two
bases, adenine and guanine, are double carbon-nitrogen rings called purines. The four
bases are commonly represented by their first letters: C, T, A, and G (Adams et al.,
1986).
DNA has a double helix structure (Figure 1), in which the sugar and phosphate
components are held together by strong phosphodiester bonds, and the nitrogenous
bases projecting from each side are bound to each others by relatively weak hydrogen
bonds (Dickerson et al., 1983; Travers et al., 1989). Each DNA subunit, consisting of
one deoxyribose, one phosphate group, and one base, is called a nucleotide (Figure 2).
When referring to the orientation of sequences along a gene, the 5’ direction is termed
“upstream”, while the 3’ direction is termed “downstream” (Rich et al., 1984).
1

Figure 1. Double helix structure of DNA (National Institutes of Health, DNA, n.d.)

2

Figure 2. Base pairing in DNA showing Adenine, Thymine, Guanine, and Cytosine
(represented by A, T, G, and C respectively); and DNA subunit, consisting of one
deoxyribose, one phosphate group, and one base, called a nucleotide (National Institutes
of Health, Base pair, n.d.)
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While DNA is formed and replicated in the cell nucleus, protein synthesis takes
place in the cytoplasm. The information contained in DNA must then be transported to
the cytoplasm and then used to dictate the composition of proteins. This involves two
processes, transcription and translation.
Transcription is the process by which an RNA sequence is formed from a DNA
template. The type of RNA produced by the transcription process is termed messenger
RNA (mRNA). To initiate mRNA transcription, one of the RNA polymerase (RNA
polymerase II) binds to a promoter site on the DNA (a promoter is a nucleotide sequence
that is located just upstream of a gene). The RNA polymerase then pulls a portion of the
DNA strands apart from one another, exposing unattached DNA bases (Conaway et al.,
1991; Mermelstein et al., 1989). One of the two DNA strands provides the template for
the sequence of mRNA nucleotides. Since mRNA can be synthesized only in the 5’ to 3’
direction, the promoter, by specifying directionality, determines which DNA strand
serves as the template. RNA polymerase moves in the 3’ to 5’ direction along the DNA
template strand, assembling the complementary mRNA strand from 5’ to 3’.
Soon after RNA synthesis begins, the 5’ end of the growing RNA molecule is
“capped” by the addition of a chemically modified guanine nucleotide (Simpson et al.,
1990). This 5’ cap appears to help to prevent the RNA molecule from being degraded
during synthesis, and later it helps to indicate the starting position for translation of the
mRNA molecule into protein. Transcription continues until a group of bases called a
termination sequence is reached. Near this point, a series of 100 to 200 adenine bases
are added to the 3’ end of the RNA molecule. This structure, known as the poly-A
tail, may be involved in stabilizing the mRNA molecule so that it is not degraded
4

when it reaches the cytoplasm (Bernstein et al., 1989; Manley et al., 1988; Wickens et al.,
1990). Finally, the DNA strands and RNA polymerase separate from the RNA strand,
leaving a transcribed single mRNA strand. This mRNA molecule is termed the primary
transcript (Wahle et al., 1992).
The primary mRNA transcript is exactly complementary to the base sequence of
the DNA template. In eukaryotes (eukaryotes are organisms that have a defined cell
nucleus, as opposed to prokaryotes, which lack a defined nucleus), an important step
takes place before this RNA transcript leaves the nucleus; sections of the RNA are
removed by nuclear enzymes, and the remaining sections are spliced together to form
the functional mRNA that will migrate to the cytoplasm (Agabian et al., 1990; Green et
al., 1991; Maniatis et al., 1991). The excised sequences are called introns, and the
sequences that are left to code for proteins are called exons (Patthy et al., 1991; Shapiro
et al., 1987; Figure 3). When gene splicing is completed, the mature transcript moves out
of the nucleus into the cytoplasm (Figure 4). Some genes contain alternative splice sites,
which allow the same primary transcript to be spliced in different ways, therefore
producing different protein products from the same gene (Guthrie et al., 1988).
Proteins are composed of one or more polypeptides, which are in turn composed
of sequences of amino acids. The body contains 20 different types of amino acids, and
the amino acid sequences that make up polypeptides must in some way be designated
by the DNA after transcription into mRNA. Individual amino acids, which compose
proteins, are encoded units of three mRNA bases, termed “codons” (Fox et al., 1987;
Lagerkrist et al., 1987). Of the 64 possible codons, 3 signal the end of a gene and are
5

Figure 3. RNA synthesis and processing (National Institutes of Health, RNA synthesis
and processing, n.d.)
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Figure 4. Mature RNA transcript transported to cytoplasm for protein synthesis (National
Institutes of Health, mRNA, n.d.)
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known as stop codons. The remaining 61 all specify amino acids; this means that most
amino acids can be specified by more than one codon (Figure 5).
Translation is the process in which mRNA provides a template for the synthesis
of a polypeptide (Merrick et al., 1992). mRNA can not, however, bind directly to amino
acids; instead, it interacts with transfer RNA (tRNA), a cloverleaf-shaped RNA strand of
about 80 nucleotides (Burbaum et al., 1991). As Figure 5 illustrates, the tRNA molecule
has a site at its 3’ end for the attachment of an amino acid by a covalent bond. At the
opposite end of the cloverleaf is a sequence of three nucleotides called the anticodon.
This sequence complementary base pairs with an appropriate codon in the mRNA (Mlot
et al., 1989).
The cytoplasmic site of protein synthesis is the ribosome, which consists of
almost equal parts of enzymatic proteins and ribosomal RNA (rRNA). The function of
rRNA is to help to bind mRNA and tRNA to the ribosome. During translation, the
ribosome first binds to an initiation site on the mRNA sequence; the site consists of a
specific codon, AUG, which specifies the amino acid methionine (which is removed from
the polypeptide before the completion of polypeptide synthesis). The ribosome then
binds the tRNA to its surface so that base pairing can occur between tRNA and mRNA.
The ribosome moves along the mRNA sequence, codon by codon, in the usual 5’ to 3’
direction; as each codon is processed, an amino acid is translated by the interaction of
mRNA and tRNA (Noller et al., 1991).
In this process, the ribosome provides an enzyme that catalyzes the formation of
covalent peptide bonds between the adjacent amino acids, resulting in a growing
polypeptide. When the ribosome arrives at a stop codon on the mRNA sequence,
8

Figure 5. The genetic code and the cloverleaf-shaped transfer RNA (tRNA) strand
(National Institutes of Health, The genetic code, n.d.)
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translation and polypeptide formation cease. The amino (NH2) terminus of the
polypeptide corresponds to the 5’ end of the mRNA strand, and the carboxyl (COOH)
terminus corresponds to the 3’ end. With synthesis completed, the mRNA, ribosome,
and polypeptide separate from one another; the polypeptide (Figure 6) is then released
into the cytoplasm (Dahlberg et al., 1989).
Before a newly synthesized polypeptide can begin its existence as functional
protein, it often undergoes further processing, termed post-translational modification
(Neurat et al., 1989). These modifications can take a variety of forms, including cleavage
into smaller polypeptide units or combination with other polypeptides to form proteins.
Other possible modifications include the addition of carbohydrate side chains to the
polypeptide (Yan et al., 1989). These modifications are needed, for example, to produce
proper folding of the mature protein or to stabilize its structure (Baldwin et al., 1989;
Creighton et al., 1992; Gethway et al., 1992).
Xenobiotic Metabolism and UDP-Glucuronosyltransferases (UGTs)
Biotransformation is important in maintaining homeostasis during exposure of
organisms to foreign substances, such as pharmaceuticals and xenobiotics. It is
accomplished by a number of enzymes with broad substrate specificities. The reactions
catalyzed by these enzymes are divided into two broad categories, called phase I and
phase II (Williams et al., 1971). Phase I reactions include, for example, hydrolysis,
reduction, and oxidation, and usually expose or introduce a functional group (e.g., -NH2,
-OH, -SH or -COOH) onto the molecule thereby increasing its hydrophilicity. Phase II
reactions include, for example, glucuronidation, sulfation, acetylation, methylation,
10

Figure 6. Primary polypeptide chain (National Institutes of Health, Amino acid, n.d.)
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glutathione conjugation, and conjugation with amino acids. Most phase II reactions
result in a large increase in xenobiotic hydrophilicity, thus promoting the excretion of
foreign compounds.
Glucuronidation, sulfation, acetylation, and methylation involve reactions with
high energy cofactors such as “acetyl coenzyme A” and “3’-phosphoadenosine-5’phosphosulfate” ( also known as PAPS), whereas conjugation with amino acids or
glutathione generally do not. Most phase II enzymes are found in the cytosol, except for
the UDP-glucuronosyltransferases, which are microsomal enzymes. Phase II reactions
generally proceed much faster than phase I reactions (for example, those catalyzed by
cytochrome P-450).
Most metabolism of ingested xenobiotics occurs in the liver. Absorbed chemicals
must first pass through the liver before entering the general circulation. Catalytic
reactions are facilitated by one of several conjugation reactions leading to the elimination
of the resultant metabolites from the cell. Detoxification of lipophilic xenobiotics is
efficiently performed by the phase II conjugation reactions, thus making them more
water-soluble to facilitate elimination, primarily by the kidney.
Glucuronide conjugation reactions of both xenobiotic and endogenous substrates
is an important mechanism of detoxification and elimination (Tukey et al., 2000; Tephly
et al., 1990; Gueraud et al., 1998). Glucuronide formation is catalyzed by a family of
UDP-glucuronosyltransferases (UGTs) which are localized in the endoplasmic reticulum
of liver and other tissues, such as the kidney, intestine, skin, brain, spleen, and nasal
mucosa. UGTs utilize uridine diphosphate-glucuronic acid (UDP-GA) as co-substrate for
the formation of glucuronides (Figure 7).
12
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Figure 7. Uridine diphosphate-glucuronic acid (UDP-GA) used as co-substrate for the
formation of glucuronides in reactions utilizing UGTs
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The UGT isoenzymes are derived from a multigene family. Based upon
differences in sequence homology and substrate specificity, two major families (UGT1A
and UGT2B) have been identified in several species, each containing several highly
homologous UGT genes. The UGT protein sequences exhibit greater than 60% similarity
within a single family.
The members of the UGT1A gene family, which comprises phenol- and bilirubinmetabolizing isoforms, all share an identical 246 amino acid carboxy terminus (Owens et
al., 1995), whereas the N-terminus of the enzyme can vary. In contrast, members of the
UGT2B gene family, the steroid-metabolizing isoforms, show little conservation among
the different isoforms of this family (Tukey et al., 2000).
The entire UGT1A family is derived from a single locus on chromosome 2 coding
for nine functional proteins (Table 1). Each of the UGT1A proteins is encoded by five
exons, with exons 2 to 5 conserved in all of the isoforms. The DNA sequence encoding
exons 2 to 5 is located at the 3’ portion of the locus. The sequences that encode the exon
1 portions of the UGTs are composed of blocks of DNA that exist as cassettes and are
aligned in series upstream of exon 2 (Figure 8). Each functional exon 1 cassette is
composed of a transcriptional start site and a 5’ consensus spliceosome recognition
sequence at the 3’ -end of the cassette. The cassettes are separated from each other by
15,000 to 25,000 base pairs. Flanking each cassette in the 5’ –direction are functional
promoter elements that are important for transcription (Tukey et al., 2000).
In contrast to the UGT1A family, the UGT2B family is composed of several
independent genes, coding for seven known functional human UGT enzymes clustered on
chromosome 4 (Jin et al., 1993; Beaulieu et al., 1997; Beaulieu et al., 1998; Belanger et
14

Isoforms of UGT1A Family
1A1
1A3
1A4
1A5
1A6
1A7
1A8
1A9
1A10

Isoforms of UGT2B Family
2B4
2B7
2B10
2B15
2B17
2B28

Table 1. Family 1 and family 2 UGT proteins

15

Figure 8. UGT1A exon 1’s and exons 2-5 (Ritter et al., 1992)
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al., 1998; Carrier et al., 2000). The UGT2 genes are composed of six exonic sequences
(Figure 9).
In previous studies (Srassburg et al., 2000; Zheng et al., 2002), several UGTs
including UGT1A9 and UGT2B7 were shown to be expressed in liver as well as in
tissues of the digestive tract including colon and esophagus (Table 2), and to play an
important role in the phase II metabolism of procarcinogenic metabolites of
benzo[a]pyrene (BaP) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). In
addition, UGT1A10 has been shown to be expressed in many target tissues for tobaccorelated cancers including the upper digestive and respiratory tracts (Table 2), and to
exhibit high activity against several BaP metabolites, including BaP-7,8-dihydrodiol.
The nicotine derived nitrosamine, NNK, is one of the most potent and abundant
procarcinogens found in tobacco and tobacco smoke (Hecht et al., 1989; Hecht et al.,
1998). NNK levels in tobacco smoke are 3- 15 times higher than that of another major
potent carcinogen in tobacco smoke, benzo[a]pyrene (Adams et al., 1987). In one
study, NNK induced predominantly lung adenocarcinomas in rodents independent of the
route of administration (Hecht et al., 1998). Another study in the Fischer 344 rat, NNK
induced pancreatic tumors (Rivenson et al., 1988) and, when applied together with the
related tobacco-specific nitrosamine, N’-nitrosonornicotine, oral cavity tumors (Hecht et
al., 1986). The cumulative dose of 1.8 mg NNK/kg body weight required to produce
lung tumors in rodents (Belinsky et al., 1990) is similar to the cumulative lifetime dose of
1.6 mg NNK/kg body weight for the average American smoking two packs of cigarettes a
day for 40 years (Hecht et al., 1989; Hecht et al., 1998). NNK is therefore considered to
be a likely causative agent for several tobacco-related cancers in humans including those
17

Exon I

II

III

IV

Figure 9. UGT2B exons 1-6
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V

VI

Upper
Digestive &
Respiratory
Tracts

UGT

Liver

Colon

Lung

Breast

Prostate

1A9

+

+

-

-

-

-

1A10

-

-

+

-

-

+

2B7

+

+

+

+

+

-

Table 2. Expression of UGT1A9, UGT1A10 and UGT2B7 (Zheng et al., 2002;
Strassburg et al., 2000)
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of the lung, oral cavity, bladder, and pancreas (Hecht et al., 1998; Rivenson et al., 1988 ).
The major metabolic pathway of NNK in most tissues is carbonyl reduction to
NNAL (Figure 10). NNK reduction to NNAL occurs in rodents, monkeys, and humans
(Hecht et al., 1998; Carmella et al., 1993; Hecht et al., 1993). It was estimated that
between 39-100% of the NNK dose is converted to NNAL in smokers (Carmella et al.,
1993). NNAL is activated via pathways similar to those observed for NNK and, like
NNK, is a potent lung and pancreatic carcinogen in rodents (Hecht et al., 1998; Rivenson
et al., 1988). Previous studies have shown that NNAL is also metabolized to its
glucuronide conjugate, NNAL-Gluc (Hecht et al., 1998; Carmella et al., 1993; Hecht et
al., 1993; Morse et al., 1990; Ren et al., 2000; Hecht et al., 1999). Although the
formation of NNAL is not a detoxification pathway for NNK, the glucuronidation of
NNAL appears to be an important mechanism for NNK detoxification.
NNAL glucuronidation can occur at both the carbinol group (NNAL-O-Gluc;
Hecht et al., 1998; Carmella et al., 1993; Hecht et al., 1993; Morse et al., 1990; Ren et al.,
2000; Figure 11) and the nitrogen on NNAL’s pyridine ring (NNAL-N-Gluc; Carmella et
al., 2002). NNAL-O-Gluc formation in human tissues is well-characterized and was
found to be mediated primarily by the hepatic enzymes, UGT2B7 and UGT1A9 (Ren et
al., 2000). The identification of NNAL-N-Gluc in human urine has been recently
reported (Carmella et al., 2002), and shown that its formation is mediated exclusively by
the hepatic enzyme, UGT1A4 (Wiener et al., 2004).
Benzo[a]pyrene is a much-studied polycyclic aromatic hydrocarbon that exhibits
high carcinogenicity in animals and is found widespread in the environment including in
emission exhausts, cigarette smoke, and char-broiled foods (Gelboin et al., 1980; IARC,
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Figure 10. Tobacco-specific nitrosamine metabolism (Hecht et al., 1998)
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Figure 11. Simplified schematic of NNK metabolism to NNAL-Gluc (A) and structures
of NNAL and NNAL-Gluc rotamers and enantiomers (Hecht et al., 1998)

22

General remarks 1983; Dipple et al., 1990). This carcinogen is metabolized by phase I
enzymes to a large number of metabolites (Figure 12) including phenols, arene oxides,
quinones, dihydrodiols, and diol epoxides, and is also conjugated by phase II enzymes
with glutathione, sulfate, and glucuronic acid to form more water-soluble, detoxified
derivatives (Gelboin et al., 1980).
Although several of these metabolites contribute to the high carcinogenicity of
BaP, many studies have clearly identified the 7,8-diol-9,10-epoxide as the primary
carcinogenic metabolite of BaP, with the anti-(+)-BaP-7R,8S-dihydrodiol-9S,10Repoxide diastereomer exhibiting enhanced mutagenic activity in vitro and in vivo
(Gelboin et al., 1980; IARC, General remarks 1983; Borgen et al., 1973; Huberman et al.,
1976; Newbold et al., 1976; Slaga et al., 1976; Yang et al., 1977). This ultimate
carcinogen is formed from BaP by two P450-mediated oxidations separated by a
hydrolysis reaction involving epoxide hydrolase-mediated formation of the proximate
carcinogen, BPD (Figure 13).
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Figure 12. Benzo[a]pyrene metabolism (Gelboin et al., 1980)
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Figure 13. Simplified schematic of BaP metabolism to BPD glucuronides and structures
of potential BPD glucuronide regioisomers and diastereomers (Gelboin et al., 1980)

25

CHAPTER ONE
DETECTION OF UGT1A10 POLYMORPHISMS AND THEIR ASSOCIATION
WITH OROLARYNGEAL CARCINOMA RISK
Abstract
UGT1A10 has been implicated as an important detoxifying enzyme for tobacco
carcinogens including benzo[a]pyrene. The UGT1A10 codon 244 (Leu>Ile) and codon
139 (Glu>Lys) missense polymorphisms are present at a low prevalence in Caucasians
but at a significantly higher prevalence in African Americans. To assess the potential
role of UGT1A10 variants as a risk factor for orolaryngeal cancer, PCR-RFLP was used
to identify UGT1A10 genotypes in buccal cell DNA specimens isolated from 115 African
American newly-diagnosed orolaryngeal cancer cases and 115 non-cancer controls
individually matched by age and race. The prevalence of the UGT1A10244Ile and
UGT1A10139Lys polymorphisms in African American controls were 0.05 and 0.07,
respectively. A significantly decreased risk for orolaryngeal cancer was observed for
subjects possessing one or more UGT1A10139Lys alleles as determined by crude analysis
or after logistic regression analysis adjusting for age, sex, smoking and alcohol
consumption. No association with risk for orolaryngeal cancer was observed for the
UGT1A10244Ile polymorphic variant. These results strongly suggest that the
UGT1A10139Lys polymorphism may play an important protective role in risk for
orolaryngeal cancer.
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Materials and Methods
Study Population
This protocol was approved by the USF Institutional Review Board and
collaborating institutions governing the rules concerning the use of human subjects in
research. For the identification of UGT1A10 polymorphisms and the determination of
prevalence in different racial groups, our subject population included the following: 1)
162 whites and 110 African Americans from New York City and 2) 200 whites, 79
African Americans, and 69 Asians (35 of Indian descent and 34 of East Asian descent)
from Tampa, FL. These individuals were participants in previous studies of genetic
polymorphisms and other risk factors for aerodigestive tract carcinoma (Richie et al.,
1997; Park et al., 2000; Elahi et al., 2002), and tissues were available for this study.
For this study, the importance of UGT1A10 polymorphisms in the risk for
orolaryngeal carcinoma was determined for 115 African American cases. All cases were
newly diagnosed patients (i.e., they were diagnosed within 1 year before study entry) who
had histologically confirmed cancer of the tongue (n=21), tonsil (n=11), pharynx or
hypopharynx (n=9), oral cavity (n=19), mixed sites (n=3), or laryngeal (n=52) squamous
cell carcinoma. Controls were recruited between 1996 and 2000 from Temple University
Hospital (Philadelphia, PA), the New York Eye and Ear Infirmary (New York, NY), and
the State University of New York at Brooklyn (New York, NY). Controls were
outpatients without cancer treated at the ear, nose, and throat or dental clinics of
participating institutions. Controls were individually matched to cases based on age
(within 5 years) and conditions described below.
To control for biases in demographics or other factors inherent in the recruitment
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of participants from institutions in different locations, controls also were matched to case
patients based on the institution of case patient. Depending on the institute, eligible cases
were identified either from admission rosters, surgical operating schedules, or cancer care
listings. 95% of controls and 98% of case patients consented to participation.
A structured questionnaire that contained items on demographics, life-long
smoking habits, and other habits was administered by trained interviewers as previously
described (Park et al., 2000). Tobacco use was categorized into pack-years. A pack-year
is defined as 1 pack of cigarettes per day for 1 year, or 4 cigars per day for 1 year, or 5
pipes per day for 1 year (Benhamou et al., 1986). Alcohol consumption was calculated as
drinks per day. One drink was defined as 12.9 g of 43% alcohol, which is roughly
equivalent to 1 oz of 86-proof liquor, or a 3.6 oz glass of wine, or a 12 oz can of beer.
Study participants were defined as drinkers of alcohol if they reported drinking a
minimum of 1 drink per week for a minimum of 10 years. Participants were classified as
never-drinkers if they consumed 1 or fewer drinks per week, light drinkers from 1 to less
than 7 drinks per week, moderate drinkers from 7 to less than 28 drinks per week, and
heavy drinkers 28 or more drinks per week.
Buccal cell samples were collected from all participants and used for the analysis
of polymorphic UGT1A10 genotypes. The same cell type was obtained for genotype
analysis for all groups. The cells were then frozen and stored until use in liquid nitrogen.

UGT1A10 Polymerase Chain Reaction Amplification Sequencing and Genotyping
Analysis
Cells were thawed and centrifuged in order to obtain a cell pellet. DNA was
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isolated from cells by incubating cell pellets with proteinase K (0.1 mg/mL) in 1%
sodium dodecyl sulfate overnight at 50 °C, extracting with phenol:chloroform, and
precipitating with ethanol as previously described (Park et al., 2000). Care was taken
during DNA purification and isolation to prevent contamination and cross-contamination
between samples during polymerase chain reaction (PCR). The purification of DNA
samples was performed in a location distant from the workstation where PCR
amplifications were performed. All equipment used for tissue blending and
homogenization was washed in a bath of concentrated chromic acid/sulfuric acid, rinsed
3 times in autoclaved double-distilled water and once in 70% ethanol, air-dried, and
autoclaved after each sample was processed.
The family 1A locus comprises divergent and individually regulated exon 1
sequences that transcribe for mRNAs that are spliced alternatively onto the 5’-end of the
sequence encoded by the common UGT exons 2-5 region. Therefore, UGT mRNAs
consist of a unique region encoded by exon 1 and a region encoded by exons 2-5 that is
common for all family 1A UGTs. To evaluate sequences that were UGT1A10 specific
and that spanned the entire UGT1A10 exon 1 region, the 5’-end of the UGT1A10
exon 1 (fragment “1”, size = 657 bp) was amplified by PCR using a sense primer
(1A10S1; 5’-TCCGCCTACTGTATCATAGCA-3’) corresponding to nucleotides
–61 through –41 relative to the translation start site in UGT1A10 exon 1 (GenBank
accession numbers AF297093 and HSU89508) and a UGT1A10 exon 1-specific antisense
primer (1A10AS1; 5’-TCTGAGAACCCTAAGAGATCA-3’) corresponding to
nucleotides 576-596 of the UGT1A10 cDNA (GenBank accession number HSU89508).
The 3’-end of UGT1A10 exon 1 (fragment “2”, size =416 bp) was amplified by PCR
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using a UGT1A10 exon 1-specific sense primer (1A10S2; 5’-CTCTTTCCTATGTCCCC
AATG-3’) corresponding to nucleotides 557-577 of the UGT1A10 cDNA and an
antisense primer (1A10AS2; 5’-CTGGAAAGAAATCTGAAATGCAACAAAC-3’)
corresponding to nucleotides 54047-54074 of the UGT family 1 loci, which corresponds
to nucleotides 90-117 downstream of UGT1A10 exon 1 (GenBank accession number
AF297093).
PCR amplifications were performed routinely in a 50-µL reaction volume
containing 50 ng of purified genomic DNA, 10 mM Tris-HCl (pH 8.3), 50mM KCl, 1.5
mM MgCl2, 0.2 mM of each of the deoxynucleotide triphosphates, 20 pmol of both sense
and antisense UGT1A10 primers, and 2.5 units (U) of Taq DNA polymerase (Boehringer
Mannheim, Indianapolis, IN). The reaction mixtures for both fragments 1 and 2
underwent the following incubations in a GeneAmp 9700 Thermocycler (Perkin-Elmer,
Foster City, CA): 1 cycle of 94 ºC for 2 minutes, 41 cycles of 94 ºC for 30 seconds, 56 ºC
for 30 seconds, and 72 ºC for 30 seconds, after which a final cycle of 7 minutes at 72 ºC
was performed. The PCR amplification integrity of all samples was confirmed by
electrophoresis in 8% polyacrylamide or 1.5% agarose gels that were stained
subsequently with ethidium bromide and evaluated under ultraviolet light using a
computerized photoimaging system (AlphaImager 2000, Alpha Innotech, San Leandro,
CA).
For dideoxy sequencing, PCR products were purified after electrophoresis in
1.5% agarose using the Qiaex II gel extraction kit (Qiagen, Valencia, CA). Dideoxy
sequencing was performed at the Molecular Biology Core Facility at the H. Lee Moffitt
Cancer Center using the same sense and antisense primers that were used for PCR
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amplification (see procedural flowchart in Figure 14).
UGT1A10 genotypes for missense polymorphisms were assessed by restriction
fragment length polymorphism (RFLP) analysis 1) to confirm polymorphic sequences in
sequenced samples, 2) to screen buccal cell DNA specimens not initially analyzed by
DNA sequencing for overall polymorphic prevalence, and 3) to screen buccal cells from
orolaryngeal carcinoma cases and matched controls. UGT1A10 exon 1 sequences were
PCR-amplified as described above, and RFLP analysis was performed at 37 ºC for 2
hours using 10-15 µL of PCR product and 5 U of the appropriate restriction enzyme (EarI
for UGT1A10 codon 139, BceA I for UGT1A10 codon 240, and EcoR V for UGT1A10
codon 244; all enzymes were purchased from New England Biolabs, Beverly, MA).
Statistical Analyses
Statistical analysis included chi-square tests for differences in genotype
frequencies and the Student t test for continuous variables such as cigarette consumption.
The risk of orolaryngeal carcinoma in relation to UGT1A10 genotypes was determined
by conditional logistic regression to calculate odds ratios (OR) and 95% confidence
intervals (CI). For all analyses, the regression models included gender, age (continuous),
pack-years of smoking (continuous), and alcohol consumption (categorical). The
statistical computer software SPSS (version 10.1) was used to perform all statistical
analyses. All statistical tests were two sided.
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Buccal Cell Collection
↓
Cell Centrifugation
↓
DNA Isolation and Purification
↓
PCR Amplification
↓
Confirmation of PCR by Electrophoresis
↓
Restriction Fragment Length Polymorphism (RFLP)
↓
Confirmation of Banding by Electrophoresis

Figure 14. Procedural flowchart
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Results
Screening for UGT1A10 Polymorphisms
Although single-nucleotide polymorphism database searches are useful for the
detection of polymorphisms in unique or non-homologous genes, database searches for
the identification of polymorphisms in UGT family 1A exon 1 regions are less useful as a
result of high nucleotide homology with other UGT family 1A members (Owens et al.,
1995).
Downstream of this region, six polymorphisms were detected by sequencing
analysis (Table 3). Three were “silent” (codons 42, 199, and 231) and three were
missense polymorphisms resulting in amino acid changes within the UGT1A10 sequence
(codons 139, 240, and 244; Figure 15). The codon 139 (G > A) polymorphism resulted
in a glutamic acid-to-lysine (Glu > Lys) amino acid change, the codon 240 (C > T)
polymorphism resulted in a threonine-to-methionine (Thr > Met) amino acid change, and
the codon 244 (C > A) polymorphism resulted in a leucine-to-isoleucine (Leu > Ile)
amino acid change, as detected by direct sequencing in two (both black), one (white), and
five (one white, four black) individuals, respectively. All three amino acid-changing
polymorphisms were confirmed by RFLP analysis (Figure 16).
Prevalence of UGT1A10 Missense Polymorphisms
To assess the prevalence of UGT1A10-specific missense polymorphisms in
different racial/ethnic groups, RFLP analysis was used to screen each of the missense
polymorphisms in healthy white, African American, and Asian individuals recruited from
Tampa or New York City (Table 3). The codon 240 (Thr > Met) polymorphism was
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Description and Prevalence of UGT1A10 Polymorphisms by Racial Group
Allelic Prevalence
a
Whitesb
Asiansc
African Americans
Codon Nucleotide Amino acid
NY
FL
Total
NY
FL
Total
East
Indian
Substitution Substitution
Asian
42
CAG to
No
0.02
Not
0.02
Not
Not
Not
CAA
Done
Done
Done
Done
139
GAG to
Glu to Lys
0.05
0.03 0.04de
Not
Not
<0.01
Not
Not
AAG
detected detected
detected detected
199
CAT to
No
0.04
Not
0.02
Not
Not
Not
CAC
Done
Done
Done
Done
231
GCC to
No
0.12
Not
0.14
Not
Not
Not
GCT
Done
Done
Done
Done
240
ACG to
Thr to Met
Not
0.01 <0.01 <0.01
<0.01 <0.01
Not
Not
ATG
detected
detected detected
244
CTC to
Leu to Ile
0.04
0.06 0.05fg <0.01
<0.01 <0.01
Not
Not
ATC
detected detected
a

Prevalence analysis was performed by direct sequencing and/or polymerase chain reaction-restriction fragment length
polymorphism analysis for 189 black subjects recruited from Mt. Vernon, NY (n = 110), and Tampa, FL (n = 79).
b
Prevalence analysis was performed by direct sequencing and/or PCR-RFLP analysis for 362 white subjects recruited from
Mt. Vernon, NY (n = 162), and Tampa, FL (n = 200).
c
The total number of Asian subjects examined included 35 Indian Asians and 34 subjects of East Asian descent.
d
Includes 11 subjects who were heterozygous and 2 subjects who were homozygous for the UGT1A10139Lys variant.
e
Prevalence was significantly greater (P < 0.005
f
P < 0.001, respectively) in African Americans compared with whites.
g
All subjects with a UGT1A10244Ile variant were heterozygous.
Table 3. Description and prevalence of UGT1A10 polymorphisms by Racial Group
(allelic prevalence is defined as the proportion of a specific allele in a population)
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Codon 139

Homozygous
wild-type

Homozygous
polymorphic

Codon 240

Homozygous
wild-type

Heterozygote

Codon 244

Homozygous
wild-type

Heterozygote

Figure 15. UGT1A10 polymorphisms identified by sequencing analysis
(homozygous is defined as containing two copies of the same allele; heterozygous is
defined as containing two different alleles of the same gene)
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Codon 139
DNA marker uncut

WT

WT

Het.

Poly.

Codon 240
DNA marker

uncut

WT

WT

Het.

Het.

Het.

Het.

Codon 244
DNA marker

uncut

WT

WT

Figure 16. RFLP Analysis for codon 139 (EarI digestion), codon 240 (BceAI digestion)
and codon 244 (EcorV digestion)
(WT: WildType; Het: Heterozygote; and Poly: Polymorphic)
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detected in 3 African Americans and 6 whites, with a resulting allelic prevalence of less
than 0.01 in both groups. Although the prevalence of both the codon 139 (Glu > Lys)
and codon 244 (Leu > Ile) polymorphisms was less than 0.01 in whites, the prevalence of
both polymorphisms wassignificantly higher (P < 0.001 for both polymorphisms) in
African Americans. The prevalence of the UGT1A10139Lys-and UGT1A10244Ile-containing
alleles was 0.04 and 0.05, respectively, in the African American cohort screened in the
current study. Although some variation in prevalence was observed for he UGT1A10
codon 139 and 244 polymorphisms for African Americans recruited from Florida versus
New York, these differences were not significant. None of the missense polymorphisms
were observed in any of the Indian or East Asian individuals screened in the current study
(same Table 3).
Analysis of UGT1A10 Polymorphisms and Orolaryngeal Carcinoma Risk
The potential role for UGT1A10 polymorphisms in the risk for orolaryngeal
carcinoma was evaluated in a case-control study of 115 African American patients with
newly diagnosed orolaryngeal carcinoma and 115 matched controls. Seventy-two
percent of cases and 62% of controls were men. The mean age for the cases and controls
was 58 years. As expected, the average pack-years of smoking was significantly higher
in case patients than in control patients (39 vs. 9 pack-years, respectively, P < 0.01).
Only 5% of case patients were never-smokers, compared with 59% of control patients. A
higher percentage of case patients than control patients were heavy drinkers of alcohol
(28 or more shots per week; 49% vs. 16%, P < 0.01).
Informative PCR results were obtained for all 115 case-control pairs (230 total
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UGT1A10 Genotype Prevalence and Risk for Orolaryngeal Carcinoma
UGT1A10
Controls
Cases
Crude OR
Adjusted OR
genotype
(%)
(%)
(95% CI)
(95% CI)a
b
Codon 139
Glu > Glu
99 (86)
108 (95.6)
1.0 (referent)
1.0 (referent)
c
Glu > Lys
16 (14)
5 (4.4)
0.29
0.20
(0.10-0.81)
(0.05-0.87)
Codon 244d
Leu > Leu
101 (91)
105 (91.3)
1.0 (referent)
1.0 (referent)
Leu > Ilec
10 (9.0)
10 (8.7)
0.96
0.94
(0.38-2.40)
(0.26-3.40)
OR, odds ratio; CI, confidence interval.
a
Adjusted for age, gender, smoking (pack-years), and alcohol consumption (categoric
variables).
b
Noninformative polymerase chain reaction analyses were obtained in two cases for
codon 139 analysis.
c
None of the subjects screened in the case-control study were homozygous for the
polymorphic variant for either the UGT1A10 codon 139 or 244 polymorphism.
d
Noninformative Polymerase chain reaction analyses were obtained in four controls for
codon 244 analysis.

Table 4. UGT1A10 genotype prevalence and risk for orolaryngeal carcinoma
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subjects) except for the UGT1A10 codon 139 polymorphism in 2 case patients and the
UGT1A10 codon 244 polymorphism in 4 control patients (Table 4). Among control
patients, the prevalence of these polymorphisms followed the Hardy-Weinberg
equilibrium and the prevalence of both polymorphisms was similar to that observed for
African Americans in New York (Table 4). There was no significant difference in allelic
prevalence between men and women among either case patients or control patients.
There was no significant difference (p > 0.05) in the prevalence of the
UGT1A10244Ile polymorphic variant between case patients (allelic prevalence, 0.043) and
control patients (allelic prevalence, 0.045). A significantly (p < 0.01) higher prevalence
of the UGT1A10139Lys polymorphic variant was observed in control patients (allelic
prevalence, 0.07) than in case patients (allelic prevalence, 0.022). As shown in Table 4,
individuals with 1 or more UGT1A10139Lys polymorphic variants exhibited a significant
decrease in risk for orolaryngeal carcinoma (ORcrude, 0.29; 95% CI, 0.10-0.81; P < 0.02).
This risk was not affected by adjusting for other factors via regression analysis (ORadjusted,
0.20; 95% CI, 0.05-0.87). There was no association between the UGT1A10244Ile
polymorphic variant and orolaryngeal carcinoma risk (ORadjusted, 0.94; 95% CI, 0.26-3.4).
Discussion
UGT1A10 has been implicated strongly in the glucuronidation of several
important BaP metabolites including BaP-7,8-dihydrodiol, the precursor to the potent
mutagen, BaP-7,8-dihydrodiol-9,10-epoxide (Fang et al., 2002). Although most family
1A UGTs are expressed in the liver, UGT1A10 is extrahepatic (Strassburg et al., 1999)
and is expressed in several target areas (Strassburg et al., 1998; Strassburg et al., 1998;
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Strassburg et al., 2000) for tobacco-induced malignancies, including the oral cavity and
the larynx (Zheng et al., 2002). Therefore, UGT1A10 may play an important role in the
detoxification of tobacco-smoke carcinogens, such as BaP, in these tissues.
Previous studies have shown that few UGT family 1A missense polymorphisms
have been identified in the exon 2-5 common region of the family 1A locus (Huang et al.,
2000). In the current study, several polymorphisms were identified in the UGT1A10specific region (UGT1A10 exon 1). Of these, three resulted in amino acid changes that
could potentially alter UGT1A10 protein function. The prevalence of all 3 missense
polymorphisms was less than 1% in whites, and none of these polymorphisms were
identified in a small cohort of Asian individuals. These data suggest that coding region
variations in UGT1A10 are rare and do not play a significant role in cancer susceptibility
in these ethnic groups. Due to their low prevalence, it was not possible to determine the
risk of orolaryngeal carcinoma associated with UGT1A10 polymorphisms in these
groups.
A significantly decreased risk of orolaryngeal carcinoma was found to be
associated with the UGT1A10 codon 139 (Glu > Lys) polymorphism but not with the
codon 244 (Leu > Ile) polymorphism in African Americans. These data are consistent
with the finding that the amino acid change from Glu > Lys for the codon 139
polymorphism is a highly nonconservative change in amino acid sequence and is
therefore a more likely candidate to alter UGT1A10 function than the Leu > Ile change
observed for the codon 244 polymorphism.
The protective effect of the UGT1A10139Lys variant on orolaryngeal carcinoma risk
observed in the current study would suggest that this variant may exhibit higher
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glucuronidating and, therefore, detoxifying activity against tobacco carcinogens like BaP7,8-dihydrodiol. Alternatively, the codon 139 polymorphism may be in linkage
disequilibrium with another marker in the UGT1 locus.
The current study has two potential limitations. The overall study sample was
relatively small, which limited our ability to determine gene-environment interactions.
There were only six case participants who never smoked cigarettes, and consequently it
was not possible to determine gene-smoking interactions. It should be emphasized that
despite this limitation, this is the largest molecular epidemiologic case-control study of
orolaryngeal carcinoma risk yet performed in African Americans.
Another potential limitation of the current study is that the control patients
recruited into the study were hospital outpatients attending dental or ear, nose, and throat
clinics. It could be proposed that they may not reflect the overall prevalence of
UGT1A10 alleles in the general population. However, as part of the International Project
on Genetic Susceptibility to Environmental Carcinogens database, a large pooled analysis
of more than 15,000 individuals without cancer was performed and no statistically
significant differences in the overall prevalence of metabolizing enzyme polymorphisms
between hospital-based and population-based controls were found (Garte et al., 2002). In
addition, in contrast with the relatively poor response rates of most studies that use
‘population’-based controls, the response rate of control patients in the current study was
very high (> 95%), thus limiting potential representation biases introduced by selective
control recruitment. Therefore, although not proven, it is unlikely that the use of
hospital-based outpatient controls substantially biased the findings of the current study.
In conclusion, polymorphisms in the UGT1A10 gene were detected and, of these,
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the codon 139 polymorphism may be an important risk factor for orolaryngeal carcinoma
in African Americans. Functional studies of UGT1A10 polymorphic variants as well as
studies determining UGT1A10 expression levels in various human tissue specimens will
be necessary to better characterize the effects of UGT1A10 polymorphisms on patient risk
for other malignancies.
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CHAPTER TWO
UGT1A9 AND UGT2B7 POLYMORPHISMS: IDENTIFICATION AND
PREVALENCE IN DIFFERENT RACIAL GROUPS
Abstract
Exposure to polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene
are important risk factors for colon cancer. Two UDP-glucuronosyltransferases,
UGT1A9 and UGT2B7, have been shown to play an important role in the phase II
metabolism of procarcinogenic metabolites of BaP. Because both enzymes are wellexpressed in digestive tract tissues including colon, it is possible that genetic variations in
either enzyme may play an important role in colon cancer risk. This study examined
UGT1A9- and UGT2B7-specific sequences for polymorphisms that potentially play a role
in cancer susceptibility. The UGT1A9 gene was analyzed by direct sequencing of
genomic DNA isolated from buccal cell swabs from 90 healthy subjects (43 African
Americans and 47 Caucasians). One silent polymorphism and two missense
polymorphisms at codons 167 (Val>Ala) and 183 (Cys>Gly) were identified. The
UGT2B7 gene was analyzed by direct sequencing of genomic DNA (exon 1) and RNA
(exon 2-6) extracted from 39 normal liver specimens from individual subjects. In
addition to seven silent polymorphisms, one previously-reported missense polymorphism
was identified. The prevalence of each missense polymorphism was determined by
PCR-RFLP analysis of buccal cell DNA from an additional 206 Caucasians, 121 African
Americans, and 59 Asians for UGT1A9, and an additional 225 Caucasians, 128 African
Americans, and 57 Asians for UGT2B7. The combined prevalence (sequencing + RFLP)
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of the UGT1A9167Ala and UGT1A9183Gly variant alleles was 0.004 and 0.025, respectively,
for Caucasians, and 0.003 and 0.01, respectively, for African Americans. None of the
missense UGT1A9 variant alleles were found in any of the Asian subjects. The
combined prevalence (sequencing + RFLP) of the UGT2B7268Tyr variant was 0.44 for
Caucasians, 0.25 for African Americans, and 0.28 for Asians. These data suggest that the
UGT2B7 His268Tyr and UGT1A9 Cys183Gly polymorphisms may be important
variables in risk for colon cancer.
Materials and Methods
Tissues and Study Population for UGT2B7 and UGT1A9
For screening the UGT2B7 gene for polymorphisms, matching genomic DNA and
total RNA, purified from normal liver specimens, were provided by the Tissue
Procurement Facility at the H. Lee Moffitt Cancer Center from individuals (n = 39)
undergoing surgery for resection of hepatocellular carcinoma; the tissues were quickfrozen at –70 ºC within 2 hours post-surgery. All subjects were Caucasian, 44% were
female, and the average age of these subjects was 64 years. All protocols involving the
analysis of tissue specimens were approved by the institutional review board at the
University of South Florida (USF) and collaborating institutions, and in accordance with
assurances filed with and approved by the United States Department of Health and
Human Services.
For the determination of UGT2B7 polymorphic prevalence in different racial
groups, our population included 225 whites, 128 African Americans, and 57 Asians.
Healthy, cancer-free Caucasian and African American subjects were recruited at the
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Lifetime Cancer Screening Center at the H. Lee Moffitt Cancer Center, and Asian
subjects were employed at H. Lee Moffitt Cancer Center/USF.
For screening the UGT1A9 gene for polymorphisms, genomic DNA was isolated
from buccal cell swabs from 90 healthy subjects (43 African Americans and 47
Caucasians). DNA was isolated from exfoliated buccal cell specimens by incubating cell
pellets with proteinase K (0.1 mg/mL) in 1% sodium dodecyl sulfate overnight at 50 °C,
extracting with phenol:chloroform, and precipitating with ethanol as previously
described. Care was taken during DNA purification and isolation to prevent
contamination and cross-contamination between samples during polymerase chain
reaction (PCR). The purification of DNA samples was performed in a location distant
from the workstation where PCR amplifications were performed. All equipment used for
tissue blending and homogenization was washed in a bath of concentrated chromic
acid/sulfuric acid, rinsed 3 times in autoclaved double-distilled water and once in 70%
ethanol, air-dried, and autoclaved after each tissue sample was processed as described
above.
For the determination of UGT1A9 polymorphic prevalence in different racial
groups, our population included 206 whites, 121 African Americans, and 59 Asians.
Healthy, cancer-free Caucasian and African American subjects were recruited at the
Lifetime Cancer Screening Center at the H. Lee Moffitt Cancer Center, and Asian
subjects were employed at H. Lee Moffitt Cancer Center/USF.
All these subjects were participants previously recruited for studies of genetic
polymorphisms and other factors in risk for aerodigestive tract cancer (Elahi et al., 2002;
Park et al., 2000; Richie et al., 1997).
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PCR Amplifications, Sequencing and Genotyping Analysis
For screening of the UGT2B7 coding region for polymorphisms, a dual PCR
amplification strategy was employed. The goal of this approach was to sequence all six
exons of UGT2B7 with minimal effort but with high gene specificity. Exon 1-encoded
sequences, which comprise nearly one-half the UGT2B7 cDNA, were individually PCRamplified using genomic DNA (purified from normal liver as described above) as
template, while UGT2B7 exons 2-6 were PCR-amplified after single-strand cDNA
synthesis of total RNA (purified from the same liver specimens used for genomic DNAPCR amplifications). The primers used for UGT2B7 exon 1 PCR-amplification were
2B7E1S (sense; 5’-TTAACTTCTTGGCTAATTTATCTTTGGACA-3’) corresponding
to nucleotides –91 through –61 relative to the translation start site in UGT2B7 exon 1
(GenBank accession number NT-030640), and 2B7E1A (antisense; 5’ATCCCACTTCTT
CATGTCAAATATTTC-3’) corresponding to nucleotides +673 through +699 relative to
the UGT2B7 exon 1/intron 1 splice junction, resulting in a PCR amplimer of 721 bp.
UGT2B7 exons 2-6 were amplified by RT-PCR using primers 2B7E2S (sense; 5’CTATGTGCTTTACTTTGACTTTTGGTTCG-3’) corresponding to nucleotides +645
through +673 of the UGT2B7 cDNA (GenBank accession number BC030974), and
2B7E2A (antisense; 5’-CCAGCTTCAAATCTCAGATATAACTAATCAT-3’)
corresponding to UGT2B7 cDNA nucleotides +1583 through +1613, resulting in a PCR
amplimer of 870 bp.
PCR amplifications of UGT2B7 exon 1 sequences were routinely performed in a
50 µL reaction volume containing 50 ng of purified DNA, 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 1.5 mM MgCl2, 0.2 mM of each of deoxynucleotide trisphosphates, 20 pmole
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of both sense and antisense UGT2B7 primers, and 2.5 units of Taq DNA polymerase.
Incubations were performed in a GenAmp 9700 Thermocycler (Perkin-Elmer Corp.,
Foster City, CA) as follows: 1 cycle of 94 ºC for 2 min, 41 cycles of 94 ºC for 30 sec, 55
ºC for 30 sec, and 72 ºC for 30 sec, followed by a final cycle of 7 min at 72 ºC.
The amplification of UGT2B7 exons 2-6 was performed after an initial RT
reaction using 3 µg of total RNA and 200 units of reverse transcriptase in a 50 min
incubation at 42 ºC, followed by PCR as described above for exon 1 sequences but using
5 µL of the RT reaction at an annealing temperature of 60 ºC. The integrity of all
samples was confirmed by electrophoresis in 8% polyacrylamide or 1.5% agarose gels
that were subsequently stained with ethidium bromide and examined over UV-light using
a computerized photoimaging system (AlphaImagerTM 2000, Alpha Innotech Corp., San
Leandro, CA).
For dideoxy sequencing, PCR products were purified after electrophoresis in
1.5% agarose using the QIAEX® II gel extraction kit (Qiagen, Valencia, CA). Dideoxy
sequencing was performed at the Department of Genetics/DNA Sequencing Facility at
the Children’s Hospital at the University of Pennsylvania Medical Center using the same
sense and antisense primers as were used for UGT2B7 amplifications.
UGT2B7 genotypes for missense polymorphisms were assessed by restriction
fragment length polymorphism (RFLP) analysis after PCR amplification using primers
2B7S (sense; 5’-TGCCTACACTATTCTAACC-3’) corresponding to nucleotides +1994
through +2012 relative to the UGT2B7 exon 1/intron 1 splice junction (GenBank
accession number NT-030640), and 2B7A (antisense; 5’-AGTGCAGAATTTTCAGAGA
-3’) corresponding to nucleotides +2555 through +2573 relative to exon 2/intron 2 splice
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junction (GenBank accession number NT-030640), using an annealing temperature of 58
ºC to produce a PCR-amplified product of 580 bp.
RFLP analysis was performed at 37 ºC for 2 hours using 10-15 µL of PCR
product and 0.1 units of the FokI restriction enzyme. Digestions were electrophoresed on
8% PAGE gels that were subsequently stained with ethidium bromide and examined over
UV-light.
The family 1A locus comprises divergent and individually regulated exon 1
sequences that transcribe for mRNAs that are spliced alternatively onto the 5’-end of the
sequence encoded by the common UGT exon 2-5 region. Therefore, UGT mRNAs
consist of a unique region encoded by exon 1 and a region encoded by exons 2-5 that is
common for all family 1A UGTs. To evaluate sequences that were UGT1A9 specific and
that spanned the entire UGT1A9 exon 1 region, PCR amplification strategy was
employed. Exon 1-encoded sequences were individually PCR-amplified using genomic
DNA (isolated from buccal cells as described above). The primers used for UGT1A9
exon 1 PCR-amplification were 1A9E1S (sense; 5’-CGCCCTCTATTGGGGTCAG-3’)
corresponding to nucleotides –100 through –82 relative to the translation start site in
UGT1A9 exon 1 (GenBank accession number AF297091), and 1A9E1A (antisense; 5’AATTTCCAAAGGTGAAGTATTCTT-3’) corresponding to nucleotides +882
through +905 relative to the UGT1A9 exon 1/intro 1 splice junction, resulting in a PCR
amplimer of 1005 bp.
PCR amplifications of UGT1A9 exon 1 sequences were performed in a 50 µL
reaction volume containing 50 ng of purified DNA, 10 mM Tris-HCl (pH 8.3), 50 mM
KCl, 1.5 mM MgCl2, 0.2 mM of each of deoxynucleotide trisphosphates, 20 pmole of
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both sense and antisense UGT1A9 primers, and 2.5 units of Taq DNA polymerase.
Incubations were performed in a GenAmp 9700 Thermocycler (Perkin-Elmer Corp.,
Foster City, CA) as follows: 1 cycle of 94 ºC for 5 min, 40 cycles of 94 ºC for 30 sec, 60
ºC for 30 sec, and 72 ºC for 1 min, followed by a final cycle of 7 min at 72 ºC. The
integrity of all samples was confirmed by electrophoresis in 8% polyacrylamide or 1.5%
agarose gels that were subsequently stained with ethidium bromide and examined over
UV-light using a computerized photoimaging system (AlphaImagerTM 2000, Alpha
Innotech Corp., San Leandro, CA).
For dideoxy sequencing, PCR products were purified after electrophoresis in
1.5% agarose using the QIAEX® II gel extraction kit (Qiagen, Valencia, CA). Dideoxy
sequencing was performed at the Department of Genetics/DNA Sequencing Facility at
the Children’s Hospital at the University of Pennsylvania Medical Center using the same
sense and antisense primers as were used for UGT1A9 amplifications.
UGT1A9 exon 1 sequences were PCR-amplified as described above, and RFLP
analysis was performed at 37 ºC for 2 hours using 10-15 µL of PCR product and 5 U of
the appropriate restriction enzyme (BbsI for UGT1A9 codon 167 and NiaIV for UGT1A9
codon 183; all enzymes were purchased from New England Biolabs, Beverly, MA).
Digestions were electrophoresed on 8% PAGE gels that were subsequently stained with
ethidium bromide and examined over UV-light (see procedural flowchart in Figure 17).
Results
Screening for UGT2B7 and UGT1A9 Polymorphisms
Eight polymorphisms were detected by sequencing analysis for UGT2B7 (Table
49

Buccal Cell Collection
↓
Cell Centrifugation
↓
DNA Isolation and Purification
↓
PCR Amplification
↓
Confirmation of PCR by Electrophoresis
↓
Restriction Fragment Length Polymorphism (RFLP)
↓
Confirmation of Banding by Electrophoresis

Figure 17. Procedural flowchart
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UGT
1A9

UGT1A9 and UGT2B7 Silent Polymorphisms
Location
Nucleotide substitution
Codon 66
CTG to TTG

2B7

UGT
1A9
2B7

Codon 124
Codon 245
Codon 246
Codon 267
Codon 285
Codon 353
Codon 354

AGA to AGG
ACG to ACA
TTA to TTC
CCT to CCA
GCC to GCA
CTG to CTC
TAT to TAC

UGT1A9 and UGT2B7 Missense Polymorphisms
Location
Nucleotide
substitution
Codon 167
GTC to GCC
Codon 183
TGC to GGC
Codon 268

CAT to TAT

Table 5. UGT1A9 and UGT2B7 polymorphisms
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Amino acid
substitution
Val to Ala
Cys to Gly
His to Tyr

5). Seven of them were “silent” (codons 124, 245, 246, 267, 285, 353, and 354) and one
previously-reported missense polymorphism (Holthe et al., 2003) resulting in an amino
acid change within the UGT2B7 sequence (codon 268; Figure 18). The codon 268 (CAT
> TAT) polymorphism resulted in a histidine-to-tyrosine (His > Tyr) amino acid change
which was confirmed by RFLP analysis (Figure 19).
Three polymorphisms were detected by sequencing analysis for UGT1A9 (Table
5). One was “silent” (codon 66) and two were missense polymorphisms resulting in
amino acid changes within the UGT1A9 sequence (codons 167 and 183; Figure 20). The
codon 167 (GTC > GCC) polymorphism resulted in a valine-to-alanine (Val > Ala)
amino acid change and the codon 183 (TGC > GGC) polymorphism resulted in a
cysteine-to-glycine (Cys > Gly) amino acid change. Both amino acid-changing
polymorphisms were confirmed by RFLP analysis (Figure 21).
Prevalence of UGT2B7 and UGT1A9 Missense Polymorphisms
To assess the prevalence of UGT2B7-specific missense polymorphism in different
racial/ethnic groups, RFLP analysis was used to screen the missense polymorphism in
healthy white, African American, and Asian individuals recruited from Tampa or New
York City (Table 6). The combined prevalence (sequencing + RFLP) of the
UGT2B7268Tyr variant was 0.44 for Caucasians, 0.25 for African Americans, and 0.28 for
Asians.
To assess the prevalence of UGT1A9-specific missense polymorphisms in
different racial/ethnic groups, RFLP analysis was used to screen the missense
polymorphisms in healthy white, African American, and Asian individuals recruited
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Homozygous Wild-Type

Heterozygote

Homozygous Polymorphic

Figure 18. UGT2B7 polymorphism (Codon 268) identified by sequencing analysis
(homozygous is defined as containing two copies of the same allele; heterozygous is
defined as containing two different alleles of the same gene)
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Codon 268
DNA marker

uncut

Het.

WT

Het.

Het.

711 bp →
489 bp →
328 bp →

147 bp →

Figure 19. RFLP Analysis for codon 268 (FokI digestion)
(WT: WildType; Het :Heterozygote; and Poly: Polymorphic)
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Poly.

Codon 167

Homozygous Wild-Type

Heterozygote

Codon 183

Homozygous Wild-Type

Heterozygote

Figure 20. UGT1A9 polymorphisms identified by sequencing analysis
(homozygous is defined as containing two copies of the same allele; heterozygous is
defined as containing two different alleles of the same gene)
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Codon 167
DNA marker

uncut

Het.

WT

711 bp →
489 bp →

328 bp →

Codon 183
DNA marker

WT

WT

WT

Het.

711 bp →
489 bp →
328 bp →

Figure 21. RFLP Analysis for codon 167 (BbsI digestion) and for codon 183 (NiaIV
digestion)
(WT: WildType and Het: Heterozygote)
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UGT1A9 and UGT2B7 missense polymorphisms and allelic prevalence
Allelic Prevalence
Codon
Nucleotide
Amino
African
Whites
Asians
Substitution
Acid
Americans
Substitution
UGT1A9
167
GTC to
Val to
0.003
0.004
Not
GCC
Ala
detected
183
TGC to
Cys to Gly
0.01
0.025
Not
GGC
detected
UGT2B7
268
CAT to
His to
0.25
0.44
0.28
TAT
Tyr

Table 6. UGT1A9 and UGT2B7 missense polymorphisms and allelic prevalence
(allelic prevalence is defined as the proportion of a specific allele in a population)
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from Tampa or New York City (Table 6). The combined prevalence (sequencing +
RFLP) of the UGT1A9167Ala and UGT1A9183Gly variant alleles was 0.004 and 0.025,
respectively, for Caucasians, and 0.003 and 0.01, respectively, for African Americans.
None of the missense UGT1A9 variant alleles were found in any of the Asian subjects.
Discussion
Previous studies have shown that few UGT family 1A missense polymorphisms
have been identified in the exon 2-5 common region of the family 1A locus (Huang et al.,
2000). In the current study, three new polymorphisms were identified by sequencing
analysis in the UGT1A9-specific region (UGT1A9 exon 1). Of these, two resulted in
amino acid changes that could potentially alter UGT1A9 protein function. The codon
167 (GTC > GCC) and the codon 183 (TGC > GGC) polymorphisms resulted in a valine
to alanine and cysteine to glycine amino acid changes, respectively. The combined
prevalence (sequencing + RFLP) of the 167ala and 183gly variant alleles were 0.004 and
0.025, respectively, for Caucasians and 0.003 and 0.01, respectively, for African
Americans. The prevalence of both missense polymorphisms was less than 1% in African
Americans, and none of these polymorphisms were identified in a small cohort of Asian
individuals. Therefore, these data suggest that coding region variations in UGT1A9 are
rare and do not play a significant role in cancer susceptibility in these ethnic groups.
In addition, eight new polymorphisms were identified by sequencing analysis in
the UGT2B7 gene. Of these, only 1 previously identified missense polymorphism
resulted in an amino acid change that could potentially alter UGT2B7 protein function.
The codon 268 (CAT > TAT) polymorphism resulted in a histidine to tyrosine amino
58

acid change. The prevalence of the 268tyr variant allele was 0.44 for Caucasians, 0.25
for African Americans and 0.28 for Asians.
In conclusion, Polymorphisms identified in the UGT1A9 gene and UGT2B7 gene
resulted in amino acid changes that may potentially alter UGT1A9 and UGT2B7 protein
function. Therefore, the codon 183 (Cys > Gly) polymorphism of UGT1A9 and the
codon 268 (His > Tyr) polymorphism of UGT2B7 could play a role in cancer risk.
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CHAPTER THREE
FUNCTIONAL CHARACTERIZATION OF THE UGT1A9183Gly POLYMORPHIC
VARIANT
Abstract
UGT1A9 is a human UDP-glucuronosyltransferase (UGT) shown to play an
important role in the phase II metabolism of procarcinogenic metabolites of
benzo(a)pyrene (BaP) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), as
well as colon carcinogens like 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5b]pyridine (Phip). As UGT1A9 is expressed in liver as well as in tissues of the digestive
tract including colon and esophagus, these enzymes may play an important role as
detoxifiers of digestive tract carcinogens. A prevalent missense polymorphism has been
previously identified at codon 183 of the UGT1A9 gene. To determine whether this
change in amino acid sequence results in aberrant UGT1A9 enzyme activity, functional
characterization of the wild-type- and variant-encoded UGT1A9 isoforms was performed
in vitro after cloning and stable transfection of wild-type and variant UGT alleles into the
non-UGT-expressing HK293 cell line. Cell homogenates were prepared from UGT1A9transfected cells and glucuronidation assays were performed using equal amount of total
cell protein against various carcinogens/carcinogen metabolites including B[a]P-7,8-diol
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), as well as other phenolic
and steroidal compounds including 1-hydroxy (OH)-pyrene, 3-OH-BaP, 7-OH-BaP, and
9-OH-BaP. Levels of UGT enzyme activity were determined in three separate
experiments by HPLC analysis and calculated both before and after normalization for cell
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homogenate of UGT1A9 protein levels as determined by Western blot analysis. A
significant (p < 0.001) 3- to 4-fold decrease in activity was observed for the
UGT1A9183Gly variant as compared to its wild-type counterpart for all substrates
analyzed. Although high levels of activity were observed for the wild-type
UGT1A9183Cys variant against NNAL, none was detected in assays with the
UGT1A9183Gly variant. Significant (p < 0.05) decreases in UGT1A9 activity were
observed prior to UGT protein normalization in assays using 9- OH-BaP or BaP-7,8diolas substrate. These results demonstrate that the UGT1A9 (Cys183Gly) polymorphism
significantly alters UGT1A9 function and could potentially play an important role as risk
modifier for digestive tract cancers.
Materials and Methods
Chemicals and Materials
3-OH-BaP, 7-OH-BaP, 9-OH-BaP, and BaP-7,8-dihydrodiol were obtained from
the National Cancer Institute Chemical Carcinogen Repository (synthesized and
characterized at Midwest Research Institute, Kansas City, MO), while NNAL was
obtained from Toronto Chemicals (Toronto, Canada). UDPGA, D,L-2-lysophosphatidyl
choline palmital C16:0, and 1-OH-pyrene were purchased from Sigma (St. Louis, MO).
14

C-UDPGA (specific activity: 300 mCi/mmol) was obtained from American

Radiolabeled Chemicals (St. Louis, MO). Dulbecco’s modified Eagle’s medium was
obtained from Mediatech (Herndon, VA) and both fetal bovine serum and geneticin
(G418) were purchased from Life Technologies (Grand Island, NY). Taq DNA
polymerase (HotMaster) was purchased from Perkin Elmer Biosystems (Foster City,
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CA), and the human UGT1A9 western blotting kit was purchased from Gentest (Woburn,
MA). HPLC-grade solvents were provided by various suppliers and used after filtration.
All other chemicals were of analytical grade and used without further purification.
RT-PCR Analysis
Total RNA was isolated from 108 UGT1A9-overexpressing cells by using the
guanidinium isothiocyanate/cesium chloride method and treatment with Dnase I. Total
RNA specimens were stored at –70 °C in individual aliquots. RT (Reverse
Transcriptase) was performed in 20 µL volumes using 3 µg total RNA, 200 units
Superscript II reverse transcriptase (GIBCO/BRL, Gaithersburg, MD), and 0.5 µg of
oligo (dT)16 primer as outlined in the manufacturer’s protocol.
For PCR (50 µL final volume), each reaction was performed using 5 µL of RT
reaction, 0.2 mM dNTPs, 5 units Taq DNA polymerase (Boehringer Mannheim), and 20
pmole of sense (5’-AGTTCTCTGATGGCTTGC-3’) and antisense (5’-TTTTACCTTA
TTTCCCACCC-3’) UGT1A9-specific primers. Reactions were incubated in a PerkinElmer 9600 Thermocycler (Perkin-Elmer Corp., Foster City, CA) for 1 cycle of 94 °C for
5 min, 40 cycles of 94 °C for 30 sec, 55 °C for 45 sec, and 72 °C for 1 min, followed by 1
cycle at 72 °C for 7 min.
Polyacrylamide gel (1.5%) electrophoresis was performed for the RT-PCR (10 µL
aliquot) reaction, and analysis and quantification of ethidium bromide-stained products
performed using a computerized photoimager system (AlphaImagerTM 2000, Alpha
Innotech Corp. San Leandro, CA). Representative RT-PCR products were purified after
electrophoresis in 1.5% agarose using the QIAEX® II gel extraction kit (Qiagen,
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Valencia, CA), and dideoxy sequencing was performed (Molecular Core Facility, H. Lee
Moffitt Cancer Center) using the same sense and antisense primers as were used for
UGT1A9 amplification, to confirm the UGT1A9 wild-type sequence of the RT-PCR
product.
TOPO® Cloning Reaction, Transformation, and Plasmid DNA Extraction
The pcDNA3.1/V5-His© TOPO® TA Expression kit provides a highly efficient, 5
minute, one-step cloning strategy for the direct insertion of Taq polymerase-amplified
PCR products into a plasmid vector (pcDNA3.1/V5-His-TOPO®; Figure 22).
The TOPO® cloning reaction (6 µL) was set up using 4 µL of PCR product, 1 µL
of sterile water, and 1 µL of TOPO® vector. The reaction was mixed gently and
incubated for 5 min at room temperature (22-23 °C). It was then placed on ice to proceed
to One Shot® Chemical transformation. 2 µL of the TOPO® Cloning reaction from the
previous step were added into a vial of One Shot® TOP10 Chemically Competent E. coli
and mixed gently. The reaction was incubated on ice for 20 min, then heat shocked for
30 sec at 42 °C, and immediately transferred to ice. 250 µL of room temperature SOC
medium was added and then the tube was capped and shaken (200 rpm) at 37 ºC for 1
hour. 100 µL from each transformation was spread on a pre-warmed selective plate
(ampicillin treated) and incubated overnight at 37 ºC. Next day, colonies were picked
from agar plates and added into a round bottom tube containing 2.5 ml of LB media
treated with ampicillin. The tubes were put in a shaker overnight to grow at 37 ºC.
Plasmid DNA extraction was done the following day using QIAprep Spin Plasmid Mini
kit.
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Figure 22. pcDNA3.1/V5-His-TOPO® vector
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RFLP analysis was performed at 37 ºC for 2 hours using 5 µL of plasmid DNA
and 5 U of the appropriate restriction enzyme (DraI) to check for right product (insert +
vector) in the correct orientation; all enzymes were purchased from New England
Biolabs, Beverly, MA). Digestions were electrophoresed on 1.5% agarose gels that were
subsequently stained with ethidium bromide and examined over UV-light.
Dideoxy sequencing was performed (Molecular Core Facility, H. Lee Moffitt
Cancer Center) using the T7 and BGH primers provided by the TOPO® Cloning kit, to
confirm the UGT1A9 wild-type sequence in the pcDNA3.1/V5-His-TOPO® vector.
Site-Directed Mutagenesis
This method uses a proof-reading polymerase to read all the way around a
plasmid and thus incorporates the primer as the new (mutant) sequence. Both of the
mutagenic oligonucleotide primers were complimentary to each other and contained the
desired mutation in order to anneal to the same sequence on opposite strands of the
plasmid (Figure 23).
PCR amplifications of the plasmid (vector + insert) sequences were routinely
performed in a 50 µL reaction volume containing 500 ng of plasmid DNA, 50 mM
MgSO4, 10 mM dNTP mixture, 10X amplification buffer, 20 pmole of both sense (5’CTTGAAGAAGGTGCACAGGGCCCTGCTCCTCTTTCC-3’) and antisense (5’GGAAAGAGGAGCAGGGCCCTGTGCACCTTCTTCAAG-3’) primers, and 2.5 units
of Platinum® Pfx DNA polymerase. Incubations were performed in a GenAmp 9700
thermocycler (Perkin-Elmer Corp., Foster City, CA) as follows: 1 cycle of 95 ºC for 30
sec and 12 cycles of 95 ºC for 30 sec, 55 ºC for 1 min, and 68 ºC for 15 min. PCR
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Figure 23. Illustration of the basic steps in a site-directed mutagenesis method
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reaction was cooled to room temperature and 2 units of restriction enzyme DpnI were
added to cut the methylated DNA (the parental plasmid DNA will be cut to pieces while
the nascent PCR DNA is left intact). The reaction was left to incubate at 37 ºC for 1 hour
followed by transformation into competent E. coli as described above. Plasmid DNA
extraction was done the following day using QIAprep Spin Plasmid Mini kit.
RFLP analysis was performed at 37 ºC for 2 hours using 5 µL of plasmid DNA
and 5 U of the appropriate restriction enzyme (ApaI) to check for right product (insert +
vector); all enzymes were purchased from New England Biolabs, Beverly, MA).
Digestions were electrophoresed on 1.5% agarose gels that were subsequently stained
with ethidium bromide and examined over UV-light.
Dideoxy sequencing was performed (Molecular Core Facility, H. Lee Moffitt
Cancer Center) using the T7 and BGH primers provided by the TOPO® Cloning kit, to
confirm the UGT1A9 polymorphic sequence in the pcDNA3.1/V5-His-TOPO® vector.
Transfection Using LipofectamineTM 2000, Cell Lines and Cell Homogenate
Preparation
HK293 (human embryonic kidney fibroblast) cells were kindly provided by Dr.
Thomas Tephly (University of Iowa, Iowa City, IA). The cells were removed from
liquid nitrogen, defrosted in a large beaker containing water at 37 °C, and immediately
transferred into cell culture dishes with media prepared earlier (for 500 ml of Modified
Eagle’s medium, add 5 ml of 100 mM sodium pyruvate solution, 5ml of 100X nonessential amino acids solution, 50 ml of fetal bovine serum, and 5 ml of
penicillin/streptomycin). The HK293 cells were grown to approximately 80% confluence
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and then transfected using DNA-Lipofectamine complexes (as described in the
manufacturer’s protocol, LipofectamineTM 2000, Invitrogen Corp., Carlsbad, CA).
For stable cell lines, the cells were passed at a 1:20 dilution into fresh growth
medium 24 hours after transfection. Selective medium was prepared earlier using 500 ml
of Dulbecco’s Modified Eagle’s medium supplemented with 4.5 mM glucose, 10 mM
HEPES, 10% fetal bovine serum, 100 U/ml penicillin, 100 µg streptomycin, and 700 µg
geneticin, and was added the following day. The cells were fed with selective medium
every 4 days; few weeks later, plates were inspected for colonies. All cells were grown
in a humidifier incubator under an atmosphere of 5% CO2.
Cells were suspended in Tris-buffered saline (25mM Tris base, 138 mM NaCl,
2.7 mM KCl; pH 7.4) and subjected to 3 rounds of freeze-thaw prior to gentle
homogenization. Cell homogenates (5-30 mg homogenate protein/ml) were stored at -70
°C in 100 µL aliquots. Total cell homogenate protein concentrations were determined
using the BCA assay (Pierce Corporation, Rockford, IL).
Western Blot Analysis
Levels of UGT1A9 expression in UGT1A9-over-expressing cell lines were
monitored by Western blot analysis using the anti-UGT1A9 antibody in a 1:5000 dilution
as per the manufacturer’s instructions (Gentest). Determinations of glucuronide
formation in wild-type versus variant UGT1A9-over-expressing cell lines were calculated
relative to the levels of UGT expression in the respective cell lines as determined by
densitometric analysis (using the AlphaImagerTM 2000 computerized photoimaging
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Figure 24. Chemical structure of substrates
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system, Alpha Innotech Corp., San Leandro, CA) of Western blots using the antiUGT1A9 antibody.
Glucuronidating Activity of UGT1A9 (Wild-Type/Polymorphic)-Over-Expressing
Cell Homogenates against NNAL
The rate of NNAL (Figure 24) glucuronidation by liver microsomes and UGT1A9
(wild-type and polymorphic variant)-over-expressing cell homogenates was determined
after a pre-incubation with D,L-2-lysophosphatidyl choline palmital C16:0 (1 mg/mg
protein) for 10 minutes at 4 °C as previously described. Briefly, liver microsomes (5 mg
protein) and cell homogenates (3 mg protein) were incubated (100 µL final volume) in 50
mM Tris-HCl (pH 7.5), 10 mM MgCl2, D,L-2-lysophosphatidyl choline palmital C16:0
(1 mg/mg protein), 4 mM 14C-UDPGA (1 µCi/100 µL reaction volume), and 5 mM
NNAL at 37 °C for 2 hours. Reactions were terminated by the addition of 1/10 volume
of 0.3 N Ba(OH)2/0.3 N ZnSO4 on ice. The precipitate was removed by centrifugation,
and the supernatant was subjected to solid phase extraction on an Oasis HLB 3 cc
reverse phase cartridge (Waters, Milford, MA) activated with acetonitrile and
equilibrated with Solvent A (0.05 M NH4AOc; pH 7.0). After loading onto the cartridge,
the sample was washed with 1 ml of Solvent A and eluted with 0.5 ml acetonitrile. The
acetonitrile was evaporated, the resulting sample diluted to 110 µL with water, and the
sample was analyzed for glucuronidated NNAL metabolites by HPLC with radioflow
detection using the following system: a Waters Associates dual-pump (model 510) HPLC
system (Milford, MA), equipped with an automatic injector (WISP model 710B), a UV
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detector operated at 254 nm (model 440), and a radioactive flow detector (IN/US
Systems, Fairfield, NJ).
HPLC was performed using a 5 µ Aquasil C18 column (4.6 mm X 250 mm,
Thermo Hypersil-Keystone, Bellefonte, PA) with gradient elution at 1 ml/min using the
following conditions: 5 min with 100% Solvent A, a linear gradient for 10 min to 30%
Solvent B (100% methanol), a subsequent linear gradient to 50% Solvent B for 10 min,
and a final linear gradient to 100% Solvent B for 5 min. The column was washed for 10
min with 100% Solvent B and regenerated for 15 min with 100% Solvent A.
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C-NNAL-

Gluc peaks were confirmed by relative retention time, and in some cases, by sensitivity to
E.coli β-glucuronidase treatment as previously described.
Glucuronidating Activity of UGT1A9 (Wild-Type/Polymorphic)-Over-Expressing
Cell Homogenates against BPD and other Benzo[a]pyrene Metabolites
The rate of B[a]P-7,8-dihydrodiol, 1-hydroxy-pyrene, and phenolic BaP
metabolites (3-, 7-, and 9-hydroxy-BaP) (see Figure 16 for chemical structures) was
determined using 0.1-1.5 mg UGT1A9-over-expresing cell homogenate (0.1 mg for 3OH-BaP, 0.3 mg for 1-OH-pyrene and 7- and 9-OH-BaP, and1.5 mg for BaP-7,8dihydrodiol). Cell homogenates were incubated (100 µL final volume) with 1mM 3-, 7-,
9-OH-BaP or 1-OH-pyrene, or 2mM BaP-7,8-dihydrodiol(±), 4 mM UDPGA, 20 mM
MgCl2, 50 mM Tris-HCl (pH 7.4). All reactions were initiated by the addition of
UDPGA. Reactions were terminated by the addition of an equal volume of acetonitrile.
Precipitates were removed by centrifugation (5 min, 10,000 x g) and supernatants were
filtered and analyzed for glucuronidated BaP metabolites by HPLC using a Beckman
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HPLC ‘Gold’ System (Fullerton, CA) consisting of a model 110B programmable solvent
module, a model 166 UV detector operated at 254 nm, a Waters automatic injector
(model 717 plus) and a β-RAM radioisotope detector (IN/US, Tampa, FL) equipped with
a 1 ml liquid flow cell. The samples were injected onto a 201TP (4.6 X 250 mm) 5 µ C18
300 Å column (VYDAC, Hesperia, CA). Separations were performed using the
following linear gradient conditions: 0-5 min, 20% Solvent A; 5-25 min, 20-40% Solvent
A; 25-30 min, 40-60% Solvent A; 30-35 min, 60-90% Solvent A, where Solvent A was
acetonitrile and was diluted at the given percentages in Solvent B (20 mM NaH2PO4, pH
4.6). The HPLC flow rate was 1 ml/min, while the scintillation fluid flow rate was 4
ml/min. The column was routinely washed with 100% Solvent A for 15 min and
equilibrated after every HPLC run with 20% Solvent A for at least 20 min (see
procedural flowchart in Figure 25).
Kinetic analysis for both wild-type and polymorphic UGT1A9-over-expressing
cell homogenates exhibiting glucuronidating activity against 1-OH-pyrene, 7-OH-BaP,
and BaP-7,8-dihydrodiol was performed as described above using an incubation time of 2
hours. The Km and Vmax for the glucuronidation of 1-OH-pyrene, 7-OH-BaP, and BPD
by both wild-type and polymorphic UGT1A9 variants were calculated after linear
regression analysis of Lineweaver-Burk plots.
Statistical Analysis
The student’s t-test (2-sided) was used for comparing rates of glucuronide
formation for the UGT1A9183Cys and UGT1A9183Gly isoforms against the different
substrates examined in this study.
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Total RNA Isolated from UGT1A9-overexpressing cells
↓
RT-PCR
↓
Polyacrylamide Gel Electrophoresis
↓
RT-PCR Product Purification
↓
Dideoxy Sequencing performed to confirm UGT1A9 Wild-Type Sequence
↓
Cloning of Wild-Type UGT1A9 Isoform into Plasmid Vector
↓
Transformation of (Vector + insert) into Chemically Competent E. coli
↓
Transformation product spread on plate (ampicillin-treated) and overnight incubation
↓
Colony Selection and Plasmid DNA Extraction
↓
RFLP Analysis to verify product in correct orientation
↓
Dideoxy Sequencing to confirm UGT1A9 Wild-Type sequence

Figure 25. Procedural flowchart (continued next page)
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Site-directed mutagenesis using proof-reading polymerase
↓
Transformation of (vector + insert) into competent E. coli
↓
Plasmid DNA extraction after colonies selection
↓
RFLP analysis performed to verify right product
↓
Dideoxy sequencing to confirm UGT1A9 polymorphic sequence
↓
HK293 cells grown and transfected using DNA-Lipofectamine complexes; plate
inspection for colonies
↓
Cell homogenates prepared from UGT1A9 transfected cells and protein concentration
determined
↓
Levels of UGT1A9 expression determined by Western blot analysis
↓
Glucuronidation assays performed using various carcinogens/carcinogen metabolites
↓
Levels of UGT enzyme activity determined by HPLC analysis and calculated before and
after normalization for cell homogenate of UGT1A9 protein levels

Figure 25. Procedural flowchart (continued)
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Results
Cloning and Sequencing
In order to obtain the whole UGT1A9 sequence, RT-PCR was performed as
described above, and cloned into the plasmid vector (pcDNA3.1/V5-His- TOPO®). The
resulting vector (insert + plasmid) was then transformed into chemically competent E.
coli, colonies were picked and plasmid DNA extracted to determine whether UGT1A9
(wild-type) had been cloned. RFLP analysis was performed using restriction enzyme
DraI and the digestion results (Figure 26) show that UGT1A9 had been cloned in the
correct orientation. To confirm the UGT1A9 wild-type sequence in the plasmid, dideoxy
sequencing was performed. The results show that no mutation (Figure 28) occurred
throughout the sequence matching the original UGT1A9 sequence from Genbank.
In order to obtain the entire UGT1A9 sequence with only one mutation at codon
183, site-directed mutagenesis was performed. After plasmid DNA extraction, RFLP
analysis was done using restriction enzyme ApaI to check for the right insert with the
mutation. ApaI cuts the polymorphic variant (UGT1A9183Gly) twice creating 2 bands on
the 1% agarose gel, while it cuts the wild-type (UGT1A9183Cys) only once, creating only 1
band (Figure 27). To confirm the UGT1A9 polymorphic sequence in the plasmid,
dideoxy sequencing was performed. The results show that only one mutation at codon
183 (Figure 28), changing TGC to GGC (Cysteine to Glycine), is present throughout the
sequence. The rest of the sequence matched the wild-type sequence.
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DNA marker

WT

WT

DNA marker

4000 bp

3384 bp

2000 bp

1684 bp
1128 bp

1000 bp
699 bp
600 bp

239 bp
200 bp

Figure 26. RFLP analysis using restriction enzyme DraI (correct orientation observed)
(vector size = 5523 b.p.; UGT1A9 size = 1627 bp)
(WT: WildType)
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DNA marker Poly.

WT

Poly. WT

Poly.

WT

WT

WT

WT

6000 bp

1000 bp

Figure 27. RFLP analysis using restriction enzyme ApaI (to check for polymorphic vs.
wild-type) (vector size = 5523 b.p.; UGT1A9 size = 1627 bp)
(WT: WildType and Poly: Polymorphic)
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Homozygous wild-type

Homozygous polymorphic

Figure 28. Section of the entire UGT1A9 sequence showing both the homozygous wildtype (with no mutation) and the homozygous polymorphic identified by sequencing
analysis (only one mutation at codon 183 changing TGC to GGC)
(homozygous is defined as containing two copies of the same allele)
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Western Blot Analysis
Levels of UGT1A9 expression in UGT1A9-over-expressing cell lines were
monitored by Western blot analysis. The levels of UGT1A9 expression in the respective
cell lines (wild-type versus variant) were determined by densitometric analysis using
UGT1A protein as standard (Figure 29). The results indicate that the UGT1A9183Gly
isoform has at least three times the level of expression compared to the UGT1A9183Cys.
NNAL Glucuronidation in UGT1A9-Over-Expressing Cell Homogenates (Wild-type
vs. Polymorphic Variant)
Previous studies have demonstrated that UGT1A9 exhibited glucuronidating
activity against NNAL (Qing et al., 2000). To determine whether the change in amino
acid sequence at codon 183 results in a change in UGT1A9 enzyme activity,
glucuronidation assays were performed using equal amounts of total cell protein against
NNAL. Levels of UGT enzyme activity were determined in three separate experiments
by HPLC analysis and calculated both before and after normalization for cell homogenate
of UGT1A9 protein levels as determined by Western blot analysis. Although high levels
of activity were observed for the wild-type UGT1A9183Cys variant against NNAL, none
was detected in assays with the UGT1A9183Gly variant (Figure 30).
BPD and other Benzo[a]pyrene metabolites in UGT1A9-Over-Expressing Cell
Homogenates (Wild-type vs. Polymorphic Variant)
Previous studies have demonstrated that UGT1A9 exhibited glucuronidating
activity against benzo[a]pyrene-7,8-dihydrodiol, 3-, 7-, 9-hydroxy-benzo[a]pyrene, and
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WT

WT

WT

Poly.

Poly.

Poly.

Figure 29. Western blot
(WT: Wildtype and Poly: Polymorphic)
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Standard protein

A

14

C-UDPGA

Retention Time (min)

B

14

C-UDPGA

Retention Time (min)

C

14

C-UDPGA

Retention Time (min)

Figure 30. HPLC analysis of NNAL-Gluc formation in liver and UGT1A9-overexpressing HK293 cells. A, Human liver microsomes were incubated using 4 mM 14CUDPGA and 5 mM NNAL as described under Materials and Methods. B, 14C-labeled
metabolites from incubations using homogenates from wild-type UGT1A9-overexpressing cells. C, 14C-labeled metabolites from incubations using homogenates from
polymorphic UGT1A9-over-expressing cells.
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A

UV Absorbance

Retention Time (min)

B

UV Absorbance

Retention Time (min)

Figure 31. HPLC analysis of BPD-Gluc formation in homogenates from UGT1A9-overexpressing HK293 cells. A, metabolites from incubations using homogenates from wildtype UGT1A9-over-expressing cells. B, metabolites from incubations using
homogenates from polymorphic UGT1A9-over-expressing cells.
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Glucuronides of
substrates
B[a]P-7,8-diolGluc
3-O-GlucB[a]P
7-O-GlucB[a]P
9-O-GlucB[a]P
1-O-Glucpyrene

Glucuronides of
substrates
B[a]P-7,8-diolGluc
3-O-GlucB[a]P
7-O-GlucB[a]P
9-O-GlucB[a]P
1-O-Glucpyrene

Before UGT protein normalization
Rate (pmol/mg/min)
Mean (wt)
Mean (poly)
Two-tailed p
value (α = 0.05)
7.76
7.36
0.0428

Ratio (poly/wt)
0.95

82.72

70.06

0.0612

0.85

102.52

95.73

0.0973

0.93

26.68

24.06

0.0190

0.90

153.8

187.84

0.0052

1.22

After UGT protein normalization
Rate (pmol/µg/min)
Mean (wt)
Mean (poly)
Two-tailed p
value (α = 0.05)
41.55
12.62
< 0.0001

Ratio (poly/wt)
0.30

442.87

120.16

< 0.0001

0.27

548.88

164.18

< 0.0001

0.30

142.84

41.26

< 0.0001

0.29

823.43

322.16

< 0.0001

0.39

Table 7. Rates of UGT1A9183Cys (wild-type) and UGT1A9183Gly (polymorphic) variant
against all substrates before and after protein normalization
(WT: Wildtype and Poly: Polymorphic)
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1-hydroxy-pyrene (Fang et al., 2002). To determine whether the change in amino acid
sequence at codon 183 results in a change in UGT1A9 enzyme activity, glucuronidation
assays were performed using equal amounts of total cell protein against each of the
mentioned substrates (Figure 31). Levels of UGT enzyme activity were determined in
three separate experiments by HPLC analysis and calculated both before and after
normalization for cell homogenate of UGT1A9 protein levels as determined by Western
blot analysis.
Significant decreases in activity were observed for the UGT1A9183Gly variant prior
to UGT protein normalization in assays using 9-OH-BaP or BaP-7,8-diol (p<0.05) as
substrate. After UGT protein normalization, significant decreases in activity (p<0.0001)
were observed for the UGT1A9183Gly variant in assays using all substrates (Table 7).

Kinetic Analysis (Km and Vmax Study)
The Km and Vmax for the glucuronidation of benzo[a]pyrene-7,8-dihydrodiol, 7OH- benzo[a]pyrene, and 1-OH-pyrene were calculated after linear regression analysis of
Lineweaver-Burk plots for both UGT1A9183Cys and UGT1A9183Gly variants (Figure 32,
33, and 34). The affinities and rates for each of the substrates as reflected by the apparent
Km and Vmax were UGT1A9183Cys > UGT1A9183Gly as summarized in Table 8.
Discussion
This is the first study to functionally characterize the UGT1A9183Gly polymorphic
variant. The levels of UGT1A9 activity that were determined by HPLC analysis and
calculated after normalization for cell homogenate of UGT1A9 protein levels, as
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A (Homozygous wild-type)

y = 31.316x + 0.1698
R2 = 0.9928

1
0.8

1/[V] 0.6
0.4
0.2
0
0.0000

0.0050

0.0100

0.0150

1/[S]

0.0200

0.0250

B (Homozygous polymorphic)

3.2

y = 129.203x + 0.2053
R2 = 0.9891

2.4

1/[V]

1.6
0.8
0
0.0000

0.0050

0.0100

0.0150

1/[S]

0.0200

0.0250

Figure 32. Linear regression analysis of Lineweaver-Burk plots for both UGT1A9183Cys
(A) and UGT1A9183Gly variants (B) using Benzo[a]pyrene-7,8-dihydrodiol as substrate
(done in triplicates using 1mM, 0.5 mM, 0.25 mM, 0.15 mM, and 0.05 mM of substrate)
(Homozygous is defined as containing two copies of the same allele; V: Velocity and S:
Substrate)
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A (Homozygous wild-type)
y = 0.3658x + 0.0058

0.1

R2 = 0.9996

0.08
1/[V]
0.06
0.04
0.02
0
0.0000

0.0500

0.1000

0.1500

0.2000

0.2500

1/[S]

B (Homozygous polymorphic)
0.18
0.15

y = 0.6387x + 0.0065
R2 = 0.993

1/[V] 0.12
0.09
0.06
0.03
0
0.0000 0.0500 0.1000 0.1500 0.2000 0.2500

1/[S]

Figure 33. Linear regression analysis of Lineweaver-Burk plots for both UGT1A9183Cys
(A) and UGT1A9183Gly variants (B) using 7-OH-Benzo[a]pyrene as substrate (done in
triplicates using 0.25 mM, 0.1 mM, 0.05 mM, 0.025 mM, 0.01 mM, and 0.005 mM of
substrate)
(Homozygous is defined as containing two copies of the same allele; V: Velocity and S:
Substrate)
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A (Homozygous wild-type)
0.025

y = 0.0803x + 0.0061
2

R = 0.9848

0.02
1/[V]
0.015
0.01
0.005
0
0.0000 0.0500 0.1000 0.1500 0.2000 0.2500

1/[S]

B (Homozygous polymorphic)
0.036
0.03

y = 0.1239x + 0.0064
R2 = 0.9919

1/[V] 0.024
0.018
0.012
0.006
0
0.0000 0.0500 0.1000 0.1500 0.2000 0.2500

1/[S]
Figure 34. Linear regression analysis of Lineweaver-Burk plots for both UGT1A9183Cys
(A) and UGT1A9183Gly variants (B) using 1-OH-pyrene as substrate (done in triplicates
using 0.25 mM, 0.1 mM, 0.05 mM, 0.025 mM, 0.01 mM, and 0.005 mM of substrate)
(Homozygous is defined as containing two copies of the same allele; V: Velocity and S:
Substrate)
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Substrate
BaP-7,8-diol
7-OH-BaP
1-OH-pyrene
Substrate
BaP-7,8-diol
7-OH-BaP
1-OH-pyrene

Km values
183Cys

(µM)
UGT1A9
UGT1A9183Gly
(wild-type)
(polymorphic)
207.44
600.11
73.19
104.42
14.0
17.81
Vmax values
UGT1A9183Cys
UGT1A9183Gly
(wild-type)
(polymorphic)
6.00
4.28
183.87
157.40
169.56
155.41

Two-tailed p
value (α = 0.05)
0.0012
0.0798
0.1105
Two-tailed p
value (α = 0.05)
0.0470
0.1711
0.1842

Table 8. Affinities and rates for each of the substrates as reflected by the apparent Km
and Vmax (all numbers in the table are calculated using the average of three reactions)
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determined by Western blot analysis, show that the UGT1A9183Gly polymorphic variant
exhibits a significantly lower enzyme activity (p < 0.0001) than the wild-type variant,
UGT1A9183Cys, for all benzo[a]pyrene metabolites tested (BaP-7,8-dihydrodiol, 3-, 7-,
and 9-OH-BaP, and 1-OH-pyrene). No activity was detected against NNAL in assays
with the UGT1A9183Gly variant.
These results are consistent with the Km and Vmax values calculated which show
that the polymorphic variant, UGT1A9183Gly, has a higher Km value, which means lower
affinity, for all substrates tested with the Km value for BaP-7,8-dihydrodiol being
significantly higher for the UGT1A9183Gly variant. The Michaelis constant, Km, is
associated with the affinity of enzyme for substrate; a larger Km means that the enzyme
binds the substrate weakly. Thus, when the rate of product formation is low, Km can be
thought of as an inverse measure of substrate binding strength. The results are also
consistent with the Vmax values calculated which show that the polymorphic variant,
UGT1A9183Gly, has a lower Vmax value, for all substrates tested with the Vmax value for
BaP-7,8-dihydrodiol being significantly lower for the UGT1A9183Gly variant. The Vmax
is defined as the maximal rate at which an enzyme catalyzes a reaction. It is expressed as
the amount of product formed per minute. The Vmax is achieved when all the enzyme
active sites are occupied with substrate molecules. This condition is called substrate
saturation.
UGT1A9 has been shown to play an important role in the phase II metabolism of
procarcinogenic metabolites of benzo[a]pyrene (BaP), 4-(methylnitrosamino)-1-(3pyridyl)-1-butanone (NNK) and other carcinogens/carcinogen metabolites. As
previously mentioned, Benzo[a]pyrene is a much-studied polycyclic aromatic
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hydrocarbon that exhibits high carcinogenicity in animals and is found widespread in the
environment including in emission exhausts, cigarette smoke, and char-broiled foods
(Gelboin et al., 1980; IARC, General remarks 1983; Dipple et al., 1990). In addition, the
nicotine derived nitrosamine, NNK, is one of the most potent and abundant
procarcinogens found in tobacco and tobacco smoke (Hecht et al., 1989; Hecht et al.,
1998). Its levels in tobacco smoke are 3- 15 times higher than that of benzo[a]pyrene
(Adams et al., 1987).
Therefore, the results of this study demonstrate that the UGT1A9 (Cys183Gly)
polymorphism significantly alters UGT1A9 function and could potentially play an
important role as a risk modifier for digestive tract cancers.
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